Lynch Syndrome Carriers' Uterine Cancer Health Assessment Using Vaginal Self-sampling and DNA Detection

What this Trial Is About

Researchers are evaluating whether self-collected vaginal swabs can detect early signs of uterine cancer or related conditions in people with Lynch syndrome who still have their uterus. The study also explores participants' willingness and ability to collect these samples themselves and how acceptable they find the process. Key questions include if vaginal DNA mutations can predict cancer risk and if existing cancer risk models apply to this group. Participants will receive up to three at-home collection kits. Each kit includes a vaginal swab for DNA collection, a swab for microbiome sampling, a vaginal pH testing kit, and detailed instructions. Self-collection is done at home, repeated up to three times at intervals of eight to nine months. Participants with abnormal test results will be referred to specialists for further clinical evaluation. During the study, participants will complete health questionnaires about lifestyle and symptoms and short surveys around the times of self-collection and at study completion. Researchers will measure how feasible and acceptable self-collected vaginal DNA testing is, monitoring for mutations linked to endometrial cancer or its precursors. The study is expected to last one to two years, with ongoing safety and clinical follow-up for those with abnormal findings.

Assessing Uterine Cancer Risk in Lynch Syndrome Carriers Using Vaginal Self-sampling and a Health Questionnaire